首页> 美国卫生研究院文献>Journal of Clinical Oncology >Efficacy Safety and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

【2h】

Efficacy Safety and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

机译：舒尼替尼单药治疗晚期肝细胞癌的疗效安全性和潜在生物标志物：II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeTo assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response.

机译：目的评估舒尼替尼在晚期肝细胞癌（HCC）患者中的安全性和疗效，并探讨舒尼替尼反应的生物标志物。

著录项

期刊名称 Journal of Clinical Oncology
作者
Andrew X. Zhu; Dushyant V. Sahani; Dan G. Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A. Catalano; Vivek Sindhwani; Lawrence S. Blaszkowsky; Sam S. Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey Meyerhardt; Jeffrey W. Clark; Eunice L. Kwak; Aram F. Hezel; Rebecca Miksad; Thomas A. Abrams; Peter C. Enzinger; Charles S. Fuchs; David P. Ryan; Rakesh K. Jain;
展开▼
作者单位

展开▼
年(卷),期 -1(27),18
年度 -1
页码 3027–3035
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 槲寄生fraxini-2在晚期肝细胞癌的治疗疗效及安全性:一项Ⅱ期临床实验 [J] . Mohamed A.Ebrahim, Hend A.El-Hadaad, Omyma A.Alemam, 中德临床肿瘤学杂志（英文版） . 2010,第008期
2. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. [J] . Zhu AX, Sahani DV, Duda DG Journal of Clinical Oncology . 2009,第18期

机译：舒尼替尼单药治疗晚期肝细胞癌的疗效，安全性和潜在生物标志物：II期研究。
3. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial [J] . Pokuri Venkata K., Tomaszewski Garin M., Ait-Oudhia Sihem, American Journal of Clinical Oncology: Cancer Clinical Trials . 2018,第4期

机译：晚期肝细胞癌（HCC）中仙烟碱和常规栓塞（TACE）组合的疗效，安全和潜在生物标志物：II期试验
4. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study [J] . ZhuA.X., AncukiewiczM., SupkoJ.G., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第6期

机译：西地尼布单药治疗晚期肝细胞癌的疗效，安全性，药代动力学和生物标志物：II期研究
5. Serologic autoantibodies against tumor associated antigens as potential biomarkers in patients suffering from Hepatocellular carcinoma and Cholangiocarcinoma [C] . Mohammad Zahid Mustafa, Zunera Tanveer, Asadullah, International Bhurban Conference on Applied Sciences and Technology . 2017

机译：抗肿瘤相关抗原的血清自身抗体可作为肝细胞癌和胆管癌患者的潜在生物标志物
6. An exploratory study for the discovery of non-invasive hepatocellular carcinoma biomarkers among high-risk hepatitis C virus infected patients. [D] . Abdalla, Moemen. 2009

机译：在高危丙型肝炎病毒感染患者中发现非侵入性肝细胞癌生物标志物的探索性研究。
7. Efficacy safety pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study [O] . Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, -1

机译：肝细胞癌中核细胞癌的疗效安全药代动力学和生物标志物：II期研究
8. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study [O] . Zhu AX, Sahani DV, Duda DG, 2009

机译：舒尼替尼单药治疗晚期肝细胞癌的疗效，安全性和潜在生物标志物：II期研究

Efficacy Safety and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅